Search results for "Virology"
showing 10 items of 2354 documents
Attitudes of Patients With Skin Tumors During the COVID-19 Pandemic
2021
Smart and resilient manufacturing in the wake of COVID-19.
2021
Since 2020, manufacturers have been facing unprecedented and extraordinary challenges with the COVID-19 outbreak, which severely disrupted manufacturing operations around the world. Some manufac- turers have shifted gears to help address dire shortages during the coronavirus pandemic. Others were thrown into deep unknowns and faced with the grim prospect of being closed down. We have seen a sprawling network of multinationals and local businesses step in to fill a void by using 3D printers to make personal protective equipment (PPE) such as face shields, respirator masks, nasal swabs and even ventilator parts. Large manufacturers attempted to rejig parts of their production lines to mass-pr…
Searching for a clinically validated definition of “asymptomatic” COVID‐19 infection
2021
Comment on "Antipsoriatic treatments during COVID-19 outbreak".
2020
The COVID-19 outbreak and rheumatologic skin diseases.
2020
Visualization of SARS-CoV-2 in the Lung.
2021
Asymptomatic SARS-CoV-2 infection and CT lung lesions: how reliable is the hypothesised association?
2021
Racing for a SARS‐CoV‐2 vaccine
2021
Interview with EMBO Members Özlem Türeci and Uğur Şahin, BioNTech, conducted by science journalist Kai Kupferschmidt.
Recent immigrants at increased pandemic risk
2020
Atypical thrombosis associated with VaxZevria (R) (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres
2021
The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to s…